Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New ovarian cancer hope for women

25.06.2003


Scientists bring early detection closer



Scientists at the Pacific Northwest Research Institute (PNRI) in Seattle announced a new biomarker for ovarian cancer today. Their discovery promises improved diagnosis of the disease, which usually remains hidden until it is too late for effective treatment.

In the July 1 issue of Cancer Research, the researchers describe a molecule, HE4, associated with ovarian cancer cells. Because the molecule is secreted readily into the blood, its presence should be detectable when simple and inexpensive clinical blood tests are developed.


"Many cancers have a high cure rate if diagnosed early," Dr. Ingegerd Hellstrom, a principal scientist at PNRI and the lead author of the new paper, says. "But not if diagnosed late. Unfortunately, ovarian carcinoma is most often diagnosed when it is already in an advanced stage. Even after surgery and chemotherapy, relapses are common."

According to the American Cancer Society, the survival statistics are dismal. Three out of four cases of ovarian cancer are diagnosed in late stages. Last year alone, nearly 14,000 women died of the disease.

The best currently available diagnostic test for ovarian cancer is CA125. It is useful in diagnosing late stage cancers, and in detecting the recurrence of tumors after chemotherapy and radiation. But it is not very effective in identifying early stage disease. It also sometimes indicates the presence of ovarian cancer where there is none. Such "false positive" results lead to dangerous, expensive, and unnecessary treatment.

In the Cancer Research study, the new biomarker, HE4, proved to be at least as effective as CA125. And where no false positive results occurred, HE4’s sensitivity to ovarian carcinoma was 40% higher than that of CA125.

"I’m very anxious to do something for patients," Hellstrom says. But there is much work to be done, laboratory studies with larger numbers of serum samples, and commercial development to design effective clinical applications of the research. The possibility that a simple and inexpensive blood test can be developed for clinical use is already being studied in a licensing agreement with Fujirebio Diagnostics Incorporated, the creator of CA125.

"Still, this is a step in the right direction," Hellstrom says. "And we are working as passionately and creatively as we can, to curtail this terrible disease."

Rich Murphy | EurekAlert!
Further information:
http://www.pnri.org/

More articles from Health and Medicine:

nachricht Discovery shows promise for treating Huntington's Disease
05.08.2020 | Ecole Polytechnique Fédérale de Lausanne

nachricht Carbon monoxide improves endurance performance
05.08.2020 | Universität Bayreuth

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: ScanCut project completed: laser cutting enables more intricate plug connector designs

Scientists at the Fraunhofer Institute for Laser Technology ILT have come up with a striking new addition to contact stamping technologies in the ERDF research project ScanCut. In collaboration with industry partners from North Rhine-Westphalia, the Aachen-based team of researchers developed a hybrid manufacturing process for the laser cutting of thin-walled metal strips. This new process makes it possible to fabricate even the tiniest details of contact parts in an eco-friendly, high-precision and efficient manner.

Plug connectors are tiny and, at first glance, unremarkable – yet modern vehicles would be unable to function without them. Several thousand plug connectors...

Im Focus: New Strategy Against Osteoporosis

An international research team has found a new approach that may be able to reduce bone loss in osteoporosis and maintain bone health.

Osteoporosis is the most common age-related bone disease which affects hundreds of millions of individuals worldwide. It is estimated that one in three women...

Im Focus: AI & single-cell genomics

New software predicts cell fate

Traditional single-cell sequencing methods help to reveal insights about cellular differences and functions - but they do this with static snapshots only...

Im Focus: TU Graz Researchers synthesize nanoparticles tailored for special applications

“Core-shell” clusters pave the way for new efficient nanomaterials that make catalysts, magnetic and laser sensors or measuring devices for detecting electromagnetic radiation more efficient.

Whether in innovative high-tech materials, more powerful computer chips, pharmaceuticals or in the field of renewable energies, nanoparticles – smallest...

Im Focus: Tailored light inspired by nature

An international research team with Prof. Cornelia Denz from the Institute of Applied Physics at the University of Münster develop for the first time light fields using caustics that do not change during propagation. With the new method, the physicists cleverly exploit light structures that can be seen in rainbows or when light is transmitted through drinking glasses.

Modern applications as high resolution microsopy or micro- or nanoscale material processing require customized laser beams that do not change during...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

“Conference on Laser Polishing – LaP 2020”: The final touches for surfaces

23.07.2020 | Event News

Conference radar for cybersecurity

21.07.2020 | Event News

Contact Tracing Apps against COVID-19: German National Academy Leopoldina hosts international virtual panel discussion

07.07.2020 | Event News

 
Latest News

Rare Earth Elements in Norwegian Fjords?

06.08.2020 | Earth Sciences

Anode material for safe batteries with a long cycle life

06.08.2020 | Power and Electrical Engineering

Turning carbon dioxide into liquid fuel

06.08.2020 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>